Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The company has been manufacturing masks since the Covid-19 outbreak in 2020
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
UCB plans to submit regulatory applications in Q3 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Subscribe To Our Newsletter & Stay Updated
